Earnings Report: Allos Therapeutics Remains Up 22%, Earnings Release Follows Positive Trial Report

Allos Therapeutics (ALTH) reports a second quarter loss of 19 cents, a penny better than the Thomson Reuters mean analyst estimate for a loss of $0.20. Net product sales were $7.9 million for the second quarter of 2010, which represents the $9 million of gross product sales net of $1.1 million of gross to net sales adjustments. The company earlier announced topline results from the company's randomized Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The primary endpoint of the trial was overall survival. Patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall patient population and a 13 percent reduction in the risk of death in the primary efficacy analysis population. I'm Marqui Mapp for SmarTrend News. For more news and market analysis, visit us at our website Trade The Trend dot com and make sure to subscribe to our You Tube channel Trade the Trend.